DNA microarray to monitor the expression of MAGE-A genes.

Zammatteo, Nathalie;Lockman, Laurence;Brasseur, Francis;De Plaen, Etienne;Remacle, José;et.al.
(2002) Clinical Chemistry : international journal of molecular diagnostics and laboratory medicine — Vol. 48, n° 1, p. 25-34 (2002)

Files

236586.pdf
  • Restricted Access
  • Adobe PDF
  • 467.23 KB

Details

Authors
  • Zammatteo, Nathalie
    Author
  • Lockman, Laurence
    Author
  • Brasseur, FrancisUCLouvain
    Author
  • De Plaen, EtienneUCLouvain
    Author
  • Boon-Falleur, ThierryUCLouvain
    Author
  • Remacle, José
    Author
Show more
Abstract
The MAGE-A genes encode antigens that are of particular interest for antitumor immunotherapy because they are strictly tumor specific and are shared by many tumors. We developed a rapid method to identify the MAGE-A genes expressed in tumors. A low-density DNA microarray was designed to discriminate between the 12 MAGE-A cDNAs amplified by PCR with only one pair of consensus primers. The assay involved reverse transcription of total RNA with oligo(dT) primer, followed by PCR amplification and hybridization on a microarray. Amplification in the presence of Biotin-16-dUTP allowed subsequent detection of the amplicons on the microarray carrying 12 capture probes, each being specific for a MAGE-A gene. Probe-amplicon hybrids were detected by a streptavidin-based method. PCR conditions were optimized for low detection limits and comparable amplification efficiencies among all MAGE-A nucleotide sequences. The microarray assay was validated with a panel of 32 samples, by comparison with well-established reverse transcription-PCR assays relying on amplification with primers specific for each gene. Virtually identical results were obtained with both methods, except for MAGE-A3 and MAGE-A5. Detection of MAGE-A5 was more sensitive with the microarray assay. Detection of MAGE-A3 was hampered by the presence of MAGE-A6, which is 98% identical: the MAGE-A3 capture probe cross-hybridized with MAGE-A6 amplicons because these sequences differed by only a single base. This post-PCR microarray assay could be useful to evaluate MAGE expression in tumors before therapeutic vaccinations with MAGE-A gene products.
Affiliations

Citations

Zammatteo, N., Lockman, L., Brasseur, F., De Plaen, E., Lurquin, C., Lobert, P.-E., Hamels, S., Boon-Falleur, T., & Remacle, J. (2002). DNA microarray to monitor the expression of MAGE-A genes. Clinical Chemistry : international journal of molecular diagnostics and laboratory medicine, 48(1), 25-34. https://hdl.handle.net/2078.5/119001 (Original work published 2002)